Andrzej Jakubowiak  Seminars in Hematology 

Slides:



Advertisements
Similar presentations
Maintenance Therapy in Multiple Myeloma
Advertisements

Treatment For Newly Diagnosed Myeloma
Ravi Vij MD Associate Professor Section of BMT and Leukemia
Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results from All Randomized Patients.
Roman Hájek on behalf of CMG March 27, 2010 Roman Hájek on behalf of CMG March 27, 2010 „Treatment standards, in Czech Republic”.
New optimism for patients with cancer n As cancer therapy evolves, new regimens and novel agents that target specific cellular processes allow a more optimistic.
Multiple Myeloma: ASH 2005 Steven Coutre, M.D. Associate Professor of Medicine Division of Hematology Stanford University School of Medicine.
Treatment with Bendamustine- Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated Ludwig H.
Maintaining Cell Identity through Global Control of Genomic Organization Gioacchino Natoli Immunity Volume 33, Issue 1, Pages (July 2010) DOI: /j.immuni
Best Upfront Treatment for MM: The Road toward a Cure Archrob Khuhapinant M.D., Ph.D. Board of Internal Medicine Board of Hematology Board of Clincial.
Second Primary Malignancies in Newly Diagnosed Multiple Myeloma Patients Treated with Lenalidomide: Analysis of Pooled Data in 2459 Patients Palumbo A.
Bortezomib Induction and Maintenance Treatment Improves Survival in Patients with Newly Diagnosed Multiple Myeloma: Extended Follow-Up of the HOVON-65/GMMG-HD4.
Evolution of the Cancer Stem Cell Model Antonija Kreso, John E. Dick Cell Stem Cell Volume 14, Issue 3, Pages (March 2014) DOI: /j.stem
IPSC Crowdsourcing: A Model for Obtaining Large Panels of Stem Cell Lines for Screening Mahendra Rao Cell Stem Cell Volume 13, Issue 4, Pages (October.
Proteasome inhibitors in multiple myeloma: 10 years later Philippe Moreau, Paul G. Richardson, Michele Cavo, Robert Z. Orlowski, Jesu´s F. San Miguel,
Normal and Leukemic Stem Cell Niches: Insights and Therapeutic Opportunities Koen Schepers, Timothy B. Campbell, Emmanuelle Passegué Cell Stem Cell Volume.
Quantitative Single-Cell Approaches to Stem Cell Research Martin Etzrodt, Max Endele, Timm Schroeder Cell Stem Cell Volume 15, Issue 5, Pages (November.
Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management S. Vincent Rajkumar Am. J. Hematol. 88:226–235, R4 신재령.
Controversies in multiple myeloma: Evidence-based update
Myeloma hope new treatment in the horizon
Treatment of early-stage Hodgkin lymphoma
From: High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study Ann Intern Med. 2004;140(2):85-93.
Building the bridge between rhabdomyosarcoma in children, adolescents and young adults: The road ahead  J. Carlijn Van Gaal, Eveline S.J.M. De Bont, Suzanne.
December 7-10, 2013 New Orleans, Louisiana
Martin Dreyling, MD, PhD  Seminars in Hematology 
How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?  Pieter Sonneveld,
Treatment of Immunoglobulin Light Chain Amyloidosis
Challenging Cases in Multiple Myeloma Panel Discussion
Evangelos Terpos, MD Department of Clinical Therapeutics,
Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry ( )  Sundar Jagannath, Rafat Abonour, Brian.
The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome by Anita D'Souza, Suzanne.
Y. Hicheri, G. Cook, C. Cordonnier  Clinical Microbiology and Infection 
Multiple Myeloma: Diagnosis and Treatment
Current Therapy for Multiple Myeloma
Jakubowiak AJ et al. Proc ASH 2010;Abstract 862.
Y. Hicheri, G. Cook, C. Cordonnier  Clinical Microbiology and Infection 
Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma,
Volume 376, Issue 9757, Pages (December 2010)
Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma.
Stem Cell Therapies in Clinical Trials: Progress and Challenges
Approaches in Newly Diagnosed Multiple Myeloma: When and What
Reduced-Intensity Allogeneic Stem Cell Transplantation in Adults and Children with Malignant and Nonmalignant Diseases: End of the Beginning and Future.
Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p  Sandy W. Wong, Ute Hegenbart, Giovanni Palladini,
Analysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American Countries  Roberto José Pessoa.
Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment- resistant Immunoglobulin Light Chain Amyloidosis With Multiple Myeloma  Shumaila.
Combined Submyeloablative and Myeloablative Dose Intense Melphalan Results in Satisfactory Responses with Acceptable Toxicity in Patients with Multiple.
Ayalew Tefferi, MD  Mayo Clinic Proceedings 
Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines.
Mitchell S. Cairo, Willi Woessmann, John Pagel 
A New Era of Renal Denervation Trials for Patients With Hypertension?
The Promise and Perils of Stem Cell Therapeutics
Eltrombopag Treatment for Primary and Secondary Thrombocytopenia Post Allogeneic and Autologous Stem Cell Transplantation is Effective and Safe  Shahram.
Sarah A. Holstein, Paul G. Richardson, Jacob P. Laubach, Philip L
Is There a Role for Autologous Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia? A Retrospective Analysis  Nicolas Novitzky, Valda.
Madeliene Parrott, Simon Rule, Michael Kelleher, Jayne Wilson 
Single Center Experience with High Dose Melphalan and Two Day Washout in Patients with Multiple Myeloma on Hemodialysis Undergoing Autologous Stem Cell.
Volume 376, Issue 9757, Pages (December 2010)
Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 
Challenges in Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)
Outcomes of Salvage Second Autologous Stem Cell Transplantation for Relapsed/Refractory Multiple Myeloma in the Era of Modern Therapy  Emily Case Ayers,
Systemic Toxoplasmosis Post Allogeneic Stem Cell Transplantation (Allo-SCT): Lessons Learned from HIV?  Marie von Lilienfeld-Toal, MD, Maria Gilleece,
Influence of Body Weight on Melphalan Dosing in Autologous Stem Cell Transplantation  Kendall Shultes, Christopher Arp, Keith Stockerl-Goldstein, Kathryn.
Improving management of neonatal infections
Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus.
Bridge to transplant following Bv+Bs regimen.
Treatment options for relapsed and refractory multiple myeloma
by Lapo Alinari, and Kristie A. Blum
Autologous Stem Cell Transplantation for POEMS Syndrome
624. Randomized Phase II Trial of Adjuvant Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer: Preliminary Results    Molecular.
Maintenance therapies in Multiple Myeloma
Presentation transcript:

Management Strategies for Relapsed/Refractory Multiple Myeloma: Current Clinical Perspectives  Andrzej Jakubowiak  Seminars in Hematology  Volume 49, Pages S16-S32 (July 2012) DOI: 10.1053/j.seminhematol.2012.05.003 Copyright © 2012 Elsevier Inc. Terms and Conditions

Figure 1 Treatment of relapsed/refractory multiple myeloma. Abbreviations: allo-SCT, allogeneic stem cell transplantation; auto-SCT, autologous stem cell transplantation; CRD, cyclophosphamide, lenalidomide, and dexamethasone; CTD, cyclophosphamide, thalidomide, and dexamethasone; CVD, cyclophosphamide, bortezomib, and dexamethasone; Cy, cyclophosphamide; Dex, dexamethasone; Len, lenalidomide; MPT, melphalan, prednisone, and thalidomide; PAD, bortezomib, doxorubicin, and dexamethasone; PegLD, pegylated liposomal doxorubicin; PN, peripheral neuropathy; Thal, thalidomide; VMP, bortezomib, melphalan, and prednisone; VTD, bortezomib, thalidomide, and dexamethasone. *Indicates that data are available from a phase 3 randomized trial. †Only if PN has recovered and there is no other therapeutic alternative. From Ludwig H, et al. Oncologist 2010;15:6-25.154 Copyright 2010 by Alphamed Press. Reproduced with permission of Alphamed Press. Permission conveyed through Copyright Clearance Center, Inc. Seminars in Hematology 2012 49, S16-S32DOI: (10.1053/j.seminhematol.2012.05.003) Copyright © 2012 Elsevier Inc. Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.